NovaBridge Biosciences (NBP)
4.02
0.00 (0.00%)
USD |
NASDAQ |
Dec 09, 16:00
3.99
-0.03
(-0.75%)
Pre-Market: 09:29
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 463.37M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 282.9% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.27% |
Profile
| NovaBridge Biosciences operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Rockville, MD. |
| URL | http://www.i-mabbiopharma.com |
| Investor Relations URL | https://www.i-mabbiopharma.com/investor-relations/ |
| HQ State/Province | Maryland |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Dec. 11, 2025 (est.) |
| Last Earnings Release | Aug. 20, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| NovaBridge Biosciences operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Rockville, MD. |
| URL | http://www.i-mabbiopharma.com |
| Investor Relations URL | https://www.i-mabbiopharma.com/investor-relations/ |
| HQ State/Province | Maryland |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Dec. 11, 2025 (est.) |
| Last Earnings Release | Aug. 20, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |